Lexicon Pharmaceuticals Overview
- Year Founded
-
1995
- Status
-
Public
- Employees
-
81
- Stock Symbol
-
LXRX
- Investments
-
4
- Share Price
-
$1.53
- (As of Friday Closing)
Lexicon Pharmaceuticals General Information
Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Contact Information
Website
www.lexpharma.comCorporate Office
- 2445 Technology Forest Boulevard
- 11th Floor
- The Woodlands, TX 77381
- United States
Corporate Office
- 2445 Technology Forest Boulevard
- 11th Floor
- The Woodlands, TX 77381
- United States
Lexicon Pharmaceuticals Timeline
Lexicon Pharmaceuticals Stock Performance
As of 20-Nov-2026, Lexicon Pharmaceuticals’s stock price is $1.53. Its current market cap is $681M with 445M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.53 | $1.67 | $1.10 - $2.68 | $681M | 445M | 2.57M | -$0.15 |
Lexicon Pharmaceuticals Financials Summary
As of 30-Sep-2026, Lexicon Pharmaceuticals has a trailing 12-month revenue of $38.5M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 702,961 | 360,109 | 109,789 | 260,930 |
| Revenue | 38,537 | 49,803 | 31,081 | 1,204 |
| EBITDA | (60,735) | (48,290) | (196,583) | (171,196) |
| Net Income | (62,353) | (50,341) | (200,403) | (177,119) |
| Total Assets | 242,021 | 184,987 | 298,420 | 229,429 |
| Total Debt | 53,536 | 62,819 | 108,397 | 106,064 |
Lexicon Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lexicon Pharmaceuticals Comparisons
Industry
Financing
Details
Lexicon Pharmaceuticals Competitors (102)
One of Lexicon Pharmaceuticals’s 102 competitors is Axsome Therapeutics, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Axsome Therapeutics | Formerly VC-backed | New York, NY | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Lexicon Pharmaceuticals Patents
Lexicon Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026206818-A1 | Methods of preparing 2',6-bis(difluoromethyl)-5-fluoro-2,4'-bipyridine | Pending | 27-Mar-2025 | ||
| WO-2026173576-A1 | Combination therapy of a glp-1 receptor agonist and a adsls inhibitor for metabolic disorders | Pending | 13-Feb-2025 | ||
| WO-2026174130-A1 | Methods of treating metabolic disease and compositions useful therein | Pending | 13-Feb-2025 | ||
| WO-2026174160-A1 | Methods of treating metabolic disease and compositions useful therein | Pending | 13-Feb-2025 | ||
| AU-2025221627-A1 | Compounds and methods of their use | Pending | 16-Feb-2024 | C07D401/12 |
Lexicon Pharmaceuticals Signals
Lexicon Pharmaceuticals Investments & Acquisitions (4)
Lexicon Pharmaceuticals’s most recent deal was a Merger/Acquisition with Symphony Icon for . The deal was made on 02-Aug-2010.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Symphony Icon | 02-Aug-2010 | Merger/Acquisition | Pharmaceuticals | ||
| Symphony Icon | 01-Jun-2007 | Joint Venture | Pharmaceuticals | ||
| Coelacanth Chemical | 12-Jul-2001 | Merger/Acquisition | Pharmaceuticals | ||
| DataWave Solutions | Corporate | Other Healthcare Technology Systems |
Lexicon Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.05 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Lexicon Pharmaceuticals FAQs
-
When was Lexicon Pharmaceuticals founded?
Lexicon Pharmaceuticals was founded in 1995.
-
Where is Lexicon Pharmaceuticals headquartered?
Lexicon Pharmaceuticals is headquartered in The Woodlands, TX.
-
What is the size of Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals has 81 total employees.
-
What industry is Lexicon Pharmaceuticals in?
Lexicon Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Lexicon Pharmaceuticals a private or public company?
Lexicon Pharmaceuticals is a Public company.
-
What is Lexicon Pharmaceuticals’s stock symbol?
The ticker symbol for Lexicon Pharmaceuticals is LXRX.
-
What is the current stock price of Lexicon Pharmaceuticals?
As of 20-Nov-2026 the stock price of Lexicon Pharmaceuticals is $1.53.
-
What is the current market cap of Lexicon Pharmaceuticals?
The current market capitalization of Lexicon Pharmaceuticals is $681M.
-
What is Lexicon Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Lexicon Pharmaceuticals is $38.5M.
-
Who are Lexicon Pharmaceuticals’s competitors?
Axsome Therapeutics, ACADIA Pharmaceuticals, Intercept Pharmaceuticals, Ionis Pharmaceuticals, and Alnylam Pharmaceuticals are some of the 102 competitors of Lexicon Pharmaceuticals.
-
What is Lexicon Pharmaceuticals’s annual earnings per share (EPS)?
Lexicon Pharmaceuticals’s EPS for 12 months was -$0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process